Tagged with BI

China Dr Xu Ting, founder, chairman and CEO of Alphamab Oncology, shares his expert opinion on the recent regulatory and healthcare reforms in China, the expertise Alphamab Oncology has in protein engineering and their mission to become a highly differentiated oncology biotech company, and Alphamab’s dual China-US development strategy in support…

France Martin Dubuc, general manager of Biogen France, discusses the company’s strong leadership in neurosciences, its commitment to pioneering the high-risk field despite the withdrawal of many industry players, the strategy to keep MS at the core of its business while developing next-generation treatments in areas like Alzheimer’s, and the important…

China Jack Wang, founder and CEO of Biomobie, shares the inspirational story behind the establishment of the company, the regenerative principle driving the technology of the Bioboostie device, and the innovative commercial partnerships he has established with leading health insurance companies in China.   My medical knowledge is limited. But I…

China Dr Yangzhou Wang, chief operations officer of Crown Bioscience (CrownBio), shares the new era of development for the company following its acquisition by a Japanese industrial conglomerate in December 2017; CrownBio’s biology-driven deep expertise in oncology drug discovery and development and how it will continue to drive the company’s growth;…

Opinion Deloitte’s Global Life Sciences & Health Care industry leader, Greg Reh gives us an exclusive insight into their forecast for 2019’s industry trends.   For companies to address mounting pressures, a digital-first mindset will be required to make business operations more efficient and bring transformational therapies to the market.   Digital…

Korea The administration of President Moon Jae-in is moving to ensure the enduring success of South Korea’s healthcare and life sciences industries through increased international collaboration. However, some pharma insiders are calling for even greater governmental support for what is still a tightly regulated sector facing pressures over pricing, exacerbated partly…

Korea Narihiko Yoshii, president of Mitsubishi Tanabe Pharma Korea unveils the value that they are bringing to Korean patients by utilising legislation regarding orphan drugs to fast track the market entry of their products. Yoshii also provides his assessment of how low drug pricing is indirectly affecting the decisions of Mitsubishi…

Opinion Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the US urges Congress to avoid restricting out-of-court drug patent settlements and to move away from anti-competitive practices that work to restrict patients access to generics and biosimilars.    Recent legislation introduced in the US Senate would…

Samsung Biologics It was less than a decade ago (2011) that Samsung Biologics was a new kid on the block amongst Korea’s booming biotech conglomerates. Since then the company has snowballed, building a series of progressively larger, more advanced facilities, culminating in its 180,000L “Dream Plant.” This facility, the largest single plant…

Korea Young-Woo Park, CEO of Y-Biologics – renowned for their library with diversity of 1011 – unveils their plan to be the first in Korea to develop the PD-1 antibody as a treatment for cancer. Mr Park provides his assessment of the current biotechnology environment in South Korea, and the growing…

Spain Damaso Molero, general manager of 3P Biopharmaceuticals, a leading Spanish CDMO, highlights the growth of the company and the need to continuously increase capacity to meet market demands. Furthermore, he touches on the innovation ecosystem in Spain and how 3P works with clients, rather than for them, to achieve long-term…

Korea Yong Zu Kim, founder and CEO of Lego Chem, discusses his company’s two areas of focus, anti-infectives and antibody drug conjugates. Dr Kim explains how his strategy has changed from solely licensing out to adopting in-house development and offers his view on the potential consolidation within the biotech sector in…